RXQ Compounding Recalls Ascorbic Acid Injection Due to Crystallization
RXQ Compounding LLC is recalling Ascorbic Acid 400 MG/ML Injection Solution because of crystallization. The recall covers all lots within expiry distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II and is a voluntary, firm-initiated action for crystallization, which fits the criteria for moderate severity involving low-risk contamination or precautionary measures without reported serious injury.
Plain-English summary
RXQ Compounding LLC has voluntarily recalled Ascorbic Acid 400 MG/ML (Non-Corn) Injection Solution, 65 mL per vial, due to crystallization. The recall includes all lots within expiry and was initiated by the firm on June 19, 2019.
The product is identified by NDC 70731-0914-65 and was distributed nationwide in the United States. The FDA classified this recall as Class II, indicating a situation where use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
Consumers and healthcare providers should stop using the recalled product and contact their pharmacist or the recalling firm for instructions on return or replacement. The recall status is currently terminated.
The recalled product
- Product
- Ascorbic Acid 400 MG/ML (Non-Corn) Injection Solution, 65 mL per vial, RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC: 70731-0914-65
- Manufacturer
- RXQ Compounding LLC
- Category
- Drug — Injection Solution
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots within expiry
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 86 recalled by RXQ Compounding LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 86 products in this recall →Related recalls
Same manufacturer · RXQ Compounding LLC
See all →- HighRXQ Compounding Recalls Niacinamide Vials Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- SevereRXQ Compounding Recalls Glutathione Injection Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- SevereFDA Recalls Fentanyl Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2019-08-14
- SevereRXQ Compounding Recalls Methylcobalamin Injectable Solution Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- SevereRXQ Compounding Recalls Folic Acid Injection Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
Same hazard · crystallization
See all →- ModerateCyproheptadine Hydrochloride Syrup Recall Due to Precipitate
FDA (Drugs) · 2026-07-29
- HighBuprenorphine injection vials show crystallization identified as buprenorphine free base
FDA (Drugs) · 2026-06-24
- ModerateDapsone Gel Recalled Nationwide for Crystallization
FDA (Drugs) · 2025-01-08
- HighDapsone Topical Gel Recalled Due to Crystallization Defect
FDA (Drugs) · 2025-01-08
- ModerateOTC cough and congestion medication recalled for crystallization
FDA (Drugs) · 2024-11-13